KemPharm (KMPH) Tops Q1 EPS by 26c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/9/2026
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
KemPharm, Inc. Reports First Quarter 2016 Results
May 12, 2016 4:06 PM EDT
Recent Clinical Development & Regulatory Highlights:
Introduced Apadaz as the proprietary name for KP201/APAPFDA Advisory Committees voted 16 to 4 in support of Apadaz approval; voted 18 to 2 against inclusion of abuse deterrent labelingGranted Fast Track designation for, and received clearance from FDA to initiate human clinical trials, of KP511, KemPharms prodrug of hydromorphone
Recent Corporate and Financial Highlights:
... More
